Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. - Wikidata - awgldk - TriplyDB

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

http://www.wikidata.org/entity/Q34648742

about

The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice Alzheimer's therapeutics: translation of preclinical science to clinical drug development Development of a self-administered web-based test for longitudinal cognitive assessment.Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6J mice.Dementia.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Cholinesterase inhibitors: drugs looking for a disease?Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1 Update on the pharmacological treatment of Alzheimer's disease Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.Therapy for Alzheimer's Disease: How Effective are Current Treatments?Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.Prescribing patterns for Alzheimer disease: survey of Canadian family physicians.Does analysis using "last observation carried forward" introduce bias in dementia research?Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain.Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial.Adding memantine to rivastigmine therapy in patients with mild-to-moderate alzheimer's disease: results of a 12-week, open-label pilot study.Short and Long-term Effects of rTMS Treatment on Alzheimer's Disease at Different Stages: A Pilot Study.Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID).Sufficiently important difference for common cold: severity reduction.The ethics of elective psychopharmacology Older patients are still under-represented in clinical trials of Alzheimer's disease Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application.Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.Psychotropic medication use in canadian long-term care patients referred for psychogeriatric consultation.Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates.Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.Vascular disease and dementias: paradigm shifts to drive research in new directions Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.Progress update: Pharmacological treatment of Alzheimer's disease.Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease Patient and caregiver quality of life in Huntington's disease Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program.Effect Size Analyses of Souvenaid in Patients with Alzheimer's Disease.Are there long-term benefits of donepezil in Alzheimer's disease?

P2860

Q21195685-41285F66-F0B6-46C1-8683-F44FAD5BF6E4 Q26829267-A54A4134-6C17-42B3-8A16-285C234A4106 Q27302092-549F1A74-81CA-4118-9756-74E876800C36 Q30401708-535025E4-873E-44E0-828A-D29F60C350DC Q30404451-327481D1-9307-4E28-8F84-AF19B21A89C0 Q30443975-34761DF7-51EE-4E2F-A26A-12924F9D7A77 Q33238993-FA26292A-9EB5-4B5F-8964-F1323505ABE6 Q33362745-B76F4966-6E4F-4B7E-8506-5FB654379511 Q33836947-67DB276F-FC4E-4B39-984B-8D32F2A87A04 Q33858264-78904CAB-CD2B-49FC-81F1-112EF9C64164 Q34209573-96FD8D5D-1CF9-4E41-AB68-94A2B6BA12DF Q34409349-A4A8D48C-9224-4AE1-A78C-AEC56131B54D Q34629649-604536AD-E572-471B-BC48-072865C11E38 Q34683821-1A308320-8198-4AB0-8105-CFDF7D321998 Q34846882-04664ACC-AF19-48EA-8B39-2CEC262E0FB4 Q34965949-038D2952-46DD-4B53-8982-CB4E9AD9B531 Q35235768-61CA47BB-E2BC-4375-A229-ECC6B423D7E1 Q35276747-84BE72E7-354C-4B96-9B79-C5112DD2A09E Q35574508-71E4E31F-F079-4FB4-9F97-2288E6F7F3C6 Q35687665-5457CA54-168E-42B2-956C-059D66EC6FEA Q35693632-2034DC77-1C67-47B4-9853-CB4A0D1E1B17 Q35831614-97596262-740C-48CB-9FB3-9A669E589C45 Q35886546-0E3F32CB-DCFB-42DE-A022-87BCB651582C Q36103290-F0A3E0F6-0CDC-4D02-A96E-9F51A7EEF104 Q36135529-A39D8D1C-C62B-4FC4-AC38-5EEF68D96DB6 Q36283014-9D25381A-6BF0-4F57-AF6C-66E520BFB078 Q36450922-A19E1EC2-A065-424D-8798-4963D705D2C4 Q36475090-2A0420CC-5E75-45B2-8102-04DD4A60DC73 Q36582006-FA946B90-BCCE-4B0B-BC22-96E7414D1552 Q36663678-F64D3CFA-BAAF-4037-9460-B9DC3FB673C8 Q36808201-94981140-76E4-4564-94E8-6BD11C5C730F Q36897422-89E938B9-5A6D-4696-BCD7-8A73B7497681 Q37129735-BE92F335-1F91-4161-8996-4D9C09FADAFB Q37129750-2CC66792-0C9D-41C2-87AC-E0ED1314A0BD Q37212835-2CC8C746-CE1C-448B-9D30-60384060ED5C Q37316293-DBA3CFFB-7F9E-4D98-A5D0-3F70A210BCB5 Q37396299-BAE6FB2D-B12D-4537-BBAA-1C549CBA660F Q37405505-C4BF5943-6DD9-47F4-8FB6-C0425B860456 Q37489106-5A225064-C0FE-4C49-9CA3-C008630A70CD Q37596399-790576F1-1AAA-4729-9A1D-A55FB6115BDF

P2860

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

http://www.wikidata.org/entity/Q34648742

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@ast

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@en

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@nl

type

label

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@ast

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@en

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@nl

prefLabel

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@ast

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@en

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@nl

P1433

Q34648742-800D06A5-4D1C-411D-8D49-D5CE183407A1

P1476

Q34648742-3C5127B7-77A0-4156-BFF8-DF723816D32B

P2093

Q34648742-05E0052E-F8ED-409B-9FEE-398B8442FC8A

Q34648742-2DC417C6-566D-44BF-8DA2-BC0F13E170D9

Q34648742-5B0276AF-FEA4-40C9-A141-38D744FE7B52

Q34648742-71B451ED-CCC9-40FD-9D30-1034A0EC95D3

Q34648742-8729FB3E-F52D-4C00-AF5D-7C84E193949B

Q34648742-CDDCD53A-12A7-414B-995A-C1206485C47A

P2860

Q34648742-00247AE0-088B-4FC8-86CA-03B58B4EE6B4

Q34648742-0158206F-584A-451E-82A9-1EE6401086E2

Q34648742-02081626-3EE1-41A3-884E-DFA63F7AFE8B

Q34648742-028F4C79-98EF-4B4C-9460-D76E7F5A9D2F

Q34648742-05932140-9F8C-496A-9950-13FC8D0784B9

Q34648742-073019D8-038C-44D9-907F-5213BAE22A71

Q34648742-0C46C102-8B9D-48F0-A8A5-7F7E6DA5D3CE

Q34648742-0D2DFA89-CF96-4291-8856-E2665457F48C

Q34648742-0DA6119C-65F0-4A39-A143-4024E7FB7D9B

Q34648742-0F21FAD7-673C-4376-AC34-5394C88CC8A7

P304

Q34648742-6BBFB55B-E760-4790-81F6-DF64CA85C2C3

P31

Q34648742-2cea04e0-aa41-4660-b070-aac5937962aa

Q34648742-D29D6DD3-FC63-49E1-9CEC-542B1690D690

P407

Q34648742-CAD972A9-574A-46A9-AC9C-FA6E9AAF4E70

P433

Q34648742-BC80DD8C-119F-420F-8832-05D7185C026A

P478

Q34648742-E123247D-5131-4D2D-A510-E9F6EB353DD6

P50

Q34648742-D043F117-189E-4832-A182-2D729CBCFFC4

P577

Q34648742-7DE0D884-21E1-4FD2-8575-9D2CD28E6581

P698

Q34648742-53B1F91C-D33C-4BDB-97CB-1E3D3D27F739

P921

Q34648742-78758952-CCC9-4DA3-9D32-64E82A6D18C4

Q34648742-E8D37A6F-4554-409C-9897-581AE140A290

P932

Q34648742-9A420040-EDC9-4EAF-9052-41374A491CD8

P1433

Canadian Medical Association Journal

P1476

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

@en

P2093

Barbara A Liu

http://www.w3.org/2001/XMLSchema#string

Kenneth K Yau

http://www.w3.org/2001/XMLSchema#string

Lyla R Khan

http://www.w3.org/2001/XMLSchema#string

Maysoon M LouLou

http://www.w3.org/2001/XMLSchema#string

Nathan Herrmann

http://www.w3.org/2001/XMLSchema#string

Thomas R Einarson

http://www.w3.org/2001/XMLSchema#string

P2860

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

The cholinergic hypothesis of Alzheimer's disease: a review of progress

Is donepezil effective for treating Alzheimer's disease?

Bias in meta-analysis detected by a simple, graphical test

Operating characteristics of a rank correlation test for publication bias

Meta-analysis in clinical trials

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

A method for meta-analysis of epidemiological studies

P304

557-564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

169

http://www.w3.org/2001/XMLSchema#string

P50

Krista L Lanctôt

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12975222

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

191283

http://www.w3.org/2001/XMLSchema#string